Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Campath MAA accepted for review by European authorities

April 26, 2000

Novelos Therapeutics initiates first U.S. trial of BAM-002

April 25, 2000

Coley initiates phase I/II trials of CpG-7909 for cancer

April 24, 2000

Preclinical results for Avax's AC Vaccine technology in breast cancer presented at AACR

April 14, 2000

SuperGen and AVI BioPharma establish marketing agreement for Avicine

April 11, 2000

Zadaxin plus chemotherapy shows promise in malignant melanoma

April 11, 2000

M-Vax shown to induce T-cell-mediated immune reactions in metastatic melanoma study

April 11, 2000

Dendreon describes preparation and use of apoptosis-inducing HLA-DR-specific MAbs

April 10, 2000

Health Canada approves Rituxan for treatment of NHL

April 7, 2000

Oncolytics Biotech's pilot canine study of Reolysin shows measurable tumor response

April 4, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...